ALKS

Alkermes is a profitable specialty pharmaceutical company built around proprietary CNS products — ARISTADA/ARISTADA INITIO, LYBALVI and VIVITROL — plus manufacturing and royalty revenue from licensee products (long-acting INVEGA, VUMERITY). FY2025 looks weak on the surface: revenue fell 5.2% to $1.48B, operating income dropped 39.6% to $254M, and net income fell 34.2% to $242M (diluted EPS $1.43, -34.1%). But the composition matters: proprietary product sales actually grew $101.1M, with LYBALVI net sales up $66.7M to $346.7M on a 19% unit increase, VIVITROL and ARISTADA both rising modestly. The earnings decline was driven instead by a $182.8M drop in higher-margin manufacturing/royalty revenue (and the Athlone facility sale) and a 32.1% jump in R&D to $324M — i.e., a mix shift and reinvestment, not commercial-franchise failure.

The balance sheet is a clear strength and supports the transition: equity grew 24.2% to $1.82B, cash rose 33.5% to $389M, current assets of $1.93B dwarf current liabilities of $543M, leverage is minimal (liabilities/equity 0.37x), and operating cash flow grew 18.6% to $521M. That financial firepower funded the strategically significant Avadel acquisition, completed February 2026 at $21.00 per share plus a $1.50 CVR, which adds LUMRYZ and a narcolepsy-experienced commercial organization — pushing Alkermes into the sleep/orexin space where it is also investing in its own pipeline.